We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





Ultrafast, On-Chip PCR that Detects SARS-CoV-2 in Only 8 Minutes Could Speed COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 27 May 2021
Print article
Image: This tiny PCR chip can amplify DNA much more quickly than conventional, benchtop PCR systems (Photo courtesy of ACS Nano 2021, DOI: 10.1021/acsnano.1c02154)
Image: This tiny PCR chip can amplify DNA much more quickly than conventional, benchtop PCR systems (Photo courtesy of ACS Nano 2021, DOI: 10.1021/acsnano.1c02154)
Researchers have developed a plasmofluidic chip that can perform PCR in only about eight minutes, which could speed COVID-19 diagnosis during current and future pandemics.

The tiny PCR chip developed by scientists at Korea Advanced Institute of Science and Technology (KAIST; Daejeon, Korea) can amplify DNA much more quickly than conventional, benchtop PCR systems. Reverse transcription-polymerase chain reaction (RT-PCR) has been the gold standard for diagnosis during the COVID-19 pandemic. However, the PCR portion of the test requires bulky, expensive machines and takes about an hour to complete, making it difficult to quickly diagnose someone at a testing site.

Currently, RT-PCR - which uses enzymes to reverse transcribe tiny amounts of viral RNA to DNA, and then amplify the DNA so that it can be detected by a fluorescent probe - is the most sensitive and reliable diagnostic method. But because the PCR portion of the test requires 30-40 cycles of heating and cooling in special machines, it takes about an hour to perform, and samples must typically be sent away to a lab, meaning that a patient usually has to wait a day or two to receive their diagnosis.

The researchers wanted to develop a plasmofluidic PCR chip that could quickly heat and cool miniscule volumes of liquids, allowing accurate point-of-care diagnosis in a fraction of the time. The team devised a postage stamp-sized polydimethylsiloxane chip with a microchamber array for the PCR reactions. When a drop of sample is added to the chip, a vacuum pulls the liquid into the microchambers, which are positioned above glass nanopillars with gold nanoislands. Any microbubbles, which could interfere with the PCR reaction, diffuse out through an air-permeable wall. When a white LED is turned on beneath the chip, the gold nanoislands on the nanopillars quickly convert light to heat, and then rapidly cool when the light is switched off.

The researchers tested the device on a piece of DNA containing a SARS-CoV-2 gene, accomplishing 40 heating and cooling cycles and fluorescence detection in only five minutes, with an additional three minutes for sample loading. The amplification efficiency was 91%, whereas a comparable conventional PCR process has an efficiency of 98%. With the reverse transcriptase step added prior to sample loading, the entire testing time with the new method could take 10-13 minutes, as opposed to about an hour for typical RT-PCR testing. The new device could provide many opportunities for rapid point-of-care diagnostics during a pandemic, according to the researchers.

Related Links:
Korea Advanced Institute of Science and Technology (KAIST)

New
Gold Supplier
SARS-CoV-2 Master Assay
Allplex SARS-CoV-2 Master Assay
New
Next-Generation Sequencing (NGS) Workstation
NGS STAR for COVID-19
New
COVID-19 Antigen Test
Instant-view PLUS COVID-19 Antigen Test
New
Influenza A/B Assay
Influenza A+B One Step Assay

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.